Add like
Add dislike
Add to saved papers

Engineering CAR T Cells with Biomaterials.

Incorporating biomaterials into the design of CAR T cells may yield new, improved versions of this immunotherapy. Two preclinical studies indicate the potential of using biodegradable nanoparticles to program circulating T cells into CAR T cells in situ , and delivering these therapeutic cells directly to solid tumors via small dissolvable sponges.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app